Ignite Creation Date:
2024-05-06 @ 11:27 AM
Last Modification Date:
2024-10-26 @ 12:46 PM
Study NCT ID:
NCT03529110
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-12
First Post:
2018-04-13
Brief Title:
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 HER2-Positive Unresectable andor Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane DESTINY-Breast03
Sponsor:
Daiichi Sankyo
Organization:
Daiichi Sankyo
Organization Data
Organization:
Daiichi Sankyo
Class:
INDUSTRY
Study ID:
DS8201-A-U302
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Daiichi Sankyo
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| AstraZeneca | INDUSTRY |
| Daiichi Sankyo Co Ltd | INDUSTRY |